Tempus AI and Daiichi Sankyo partnered to develop proof-of-concept multimodal AI models intended to improve oncology ADC development by increasing the probability of success through better patient selection. The collaboration provides Daiichi Sankyo access to Tempus foundation models and AI expertise, including PRISM2. Both sides said they plan to focus on biomarker discovery and patient stratification and to benchmark potential control arms for future clinical trials using real-world data. The deal also aligns with a broader wave of oncology AI partnerships aimed at reducing trial development risk, particularly around selecting the right patient populations and improving trial comparability. For ADC developers, the partnership underscores an operational shift: models are being used not only for stratification but also to structure evidence generation for regulatory-grade trial designs.